B
Bullisch
Bullisch · 25%TEVA
$17.88
Szenariopreis
$39.970
-0.416 (-1.04%)Zum Schluss
Loading chart…
- Hoch
- 40.500
- Eröffnung
- 39.740
- Volumengewichteter Durchschnittskurs
- 39.98
- Volumen
- 4.65M
- Marktkap.
- 18.42B
- Tief
- 39.460
- Umsatz
- 185.79M
- EV/EBITDA, TTM
- 35.83
Teva Pharmaceutical Industries Ltd is a Israeli-based pharmaceutical company. The Company operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.
KI-Analyse of Teva Pharmaceutical Industries Limited.. (TEVA)
KaufenTeva Pharmaceutical Industries Ltd is a good buy right now, trading at $39.41 with a forward P/E of 7.05, indicating strong value compared to its earnings potential. The recent FDA approval of Weltruza is expected to significantly enhance Teva's market share in the mental health sector, driving future revenue growth. However, the stock has seen insider selling increase by 764.83% recently, which is a notable risk.
Analystenbewertungen (26)
-10.66% Abwärtspotenzial
Halten
4 Kaufen
17 Halten
5 Verkaufen
Aktuell: 39.97
Tief
29.00
Durchschnitt
35.71
Hoch
40.00
JPMorgan
Übergewichten
$50
2026-10-11
JPMorgan
2026-10-11
Kursziel
$50
Übergewichten
TD Cowen
Kaufen
$55
2026-10-01
TD Cowen
2026-10-01
Kursziel
$55
Kaufen
Oppenheimer
Überdurchschnittlich
$50
2026-09-23
Oppenheimer
2026-09-23
Kursziel
$50
Überdurchschnittlich
Leerink
Überdurchschnittlich
$45
2026-09-09
Leerink
2026-09-09
Kursziel
$45
Überdurchschnittlich
UBS
Kaufen
$48
2026-09-04
UBS
2026-09-04
Kursziel
$48
Kaufen
Bewertungskennzahlen
Das aktuelle erwartete KGV von Teva Pharmaceutical Industries Limited.. (TEVA) beträgt 12.55, verglichen mit dem 5-Jahres-Durchschnitt von 6.07.
Alphio-AI-Kursszenarien für TEVA
Szenariopreise sind das letzte monatliche Prognoseband des laufenden Jahres. Die Wahrscheinlichkeiten sind feste Modellgewichte (25 / 50 / 25), keine Garantien.
Whales, die TEVA halten
Event-Zeitleiste
News
- 9.510-25Fool
Neurocrine Biosciences Reports 39% Revenue Growth in Q2 2026
1.010-12NewsfilterTeva Pharmaceuticals to Host R&D Day on November 11, 2026
9.010-09stocktwitsTeva Receives FDA Approval for New Schizophrenia Injection
2.010-09CNBCSpaceX Boosts Starlink Service, Impacting Telecom Stocks
- 2.010-09Newsfilter
Teva Launches WELTRUZA™ for Schizophrenia Treatment
TEVA FAQ – beantwortet von Alphio AI
Teva Pharmaceutical Industries Ltd is a Israeli-based pharmaceutical company. The Company operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Teva Pharmaceutical Industries Ltd is a good buy right now, trading at $39.41 with a forward P/E of 7.05, indicating strong value compared to its earnings potential. The recent FDA approval of Weltruza is expected to significantly enhance Teva's market share in the mental health sector, driving future revenue growth. However, the stock has seen insider selling increase by 764.83% recently, which is a notable risk.
26 analysts cover TEVA: 4 rate it Buy, 17 Hold and 5 Sell. The average price target is 35.71.
Community
Mehr ↗
$TEVA | UBS Reaffirms Buy Rating on Teva with $48 Price Target, Citing Celiac R&D Progress and 2027 Catalyst Pipeline UBS remains positive on Teva, pointing to Celiac-related developments and a steady pipeline of catalysts through 2027 as key drivers for long-term growth.
Mehr anzeigen
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.